Heart Failure Association, Heart Failure Society of America, and Japanese Heart Failure Society Position Statement on Endomyocardial Biopsy
Copyright © 2021. Published by Elsevier Inc..
Endomyocardial biopsy (EMB) is an invasive procedure, globally most often used for the monitoring of heart transplant rejection. In addition, EMB can have an important complementary role to the clinical assessment in establishing the diagnosis of diverse cardiac disorders, including myocarditis, cardiomyopathies, drug-related cardiotoxicity, amyloidosis, other infiltrative and storage disorders, and cardiac tumors. Improvements in EMB equipment and the development of new techniques for the analysis of EMB samples has significantly improved the diagnostic precision of EMB. The present document is the result of the Trilateral Cooperation Project between the Heart Failure Association of the European Society of Cardiology, Heart Failure Society of America, and the Japanese Heart Failure Society. It represents an expert consensus aiming to provide a comprehensive, up-to-date perspective on EMB, with a focus on the following main issues: (1) an overview of the practical approach to EMB, (2) an update on indications for EMB, (3) a revised plan for heart transplant rejection surveillance, (4) the impact of multimodality imaging on EMB, and (5) the current clinical practice in the worldwide use of EMB.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:27 |
|---|---|
| Enthalten in: |
Journal of cardiac failure - 27(2021), 7 vom: 01. Juli, Seite 727-743 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Seferović, Petar M [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Amyloidosis |
|---|
| Anmerkungen: |
Date Completed 01.11.2021 Date Revised 01.11.2021 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.cardfail.2021.04.010 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM325717273 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM325717273 | ||
| 003 | DE-627 | ||
| 005 | 20231225193029.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.cardfail.2021.04.010 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1085.xml |
| 035 | |a (DE-627)NLM325717273 | ||
| 035 | |a (NLM)34022400 | ||
| 035 | |a (PII)S1071-9164(21)00150-0 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Seferović, Petar M |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Heart Failure Association, Heart Failure Society of America, and Japanese Heart Failure Society Position Statement on Endomyocardial Biopsy |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 01.11.2021 | ||
| 500 | |a Date Revised 01.11.2021 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2021. Published by Elsevier Inc. | ||
| 520 | |a Endomyocardial biopsy (EMB) is an invasive procedure, globally most often used for the monitoring of heart transplant rejection. In addition, EMB can have an important complementary role to the clinical assessment in establishing the diagnosis of diverse cardiac disorders, including myocarditis, cardiomyopathies, drug-related cardiotoxicity, amyloidosis, other infiltrative and storage disorders, and cardiac tumors. Improvements in EMB equipment and the development of new techniques for the analysis of EMB samples has significantly improved the diagnostic precision of EMB. The present document is the result of the Trilateral Cooperation Project between the Heart Failure Association of the European Society of Cardiology, Heart Failure Society of America, and the Japanese Heart Failure Society. It represents an expert consensus aiming to provide a comprehensive, up-to-date perspective on EMB, with a focus on the following main issues: (1) an overview of the practical approach to EMB, (2) an update on indications for EMB, (3) a revised plan for heart transplant rejection surveillance, (4) the impact of multimodality imaging on EMB, and (5) the current clinical practice in the worldwide use of EMB | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Endomyocardial biopsy | |
| 650 | 4 | |a amyloidosis | |
| 650 | 4 | |a cardiac tumors | |
| 650 | 4 | |a cardiomyopathy | |
| 650 | 4 | |a cardiotoxicity | |
| 650 | 4 | |a heart failure | |
| 650 | 4 | |a heart transplantation | |
| 650 | 4 | |a myocarditis | |
| 650 | 4 | |a sarcoidosis | |
| 700 | 1 | |a Tsutsui, Hiroyuki |e verfasserin |4 aut | |
| 700 | 1 | |a Mcnamara, Dennis M |e verfasserin |4 aut | |
| 700 | 1 | |a Ristić, Arsen D |e verfasserin |4 aut | |
| 700 | 1 | |a Basso, Cristina |e verfasserin |4 aut | |
| 700 | 1 | |a Bozkurt, Biykem |e verfasserin |4 aut | |
| 700 | 1 | |a Cooper, Leslie T |e verfasserin |4 aut | |
| 700 | 1 | |a Filippatos, Gerasimos |e verfasserin |4 aut | |
| 700 | 1 | |a Ide, Tomomi |e verfasserin |4 aut | |
| 700 | 1 | |a Inomata, Takayuki |e verfasserin |4 aut | |
| 700 | 1 | |a Klingel, Karin |e verfasserin |4 aut | |
| 700 | 1 | |a Linhart, Aleš |e verfasserin |4 aut | |
| 700 | 1 | |a Lyon, Alexander R |e verfasserin |4 aut | |
| 700 | 1 | |a Mehra, Mandeep R |e verfasserin |4 aut | |
| 700 | 1 | |a Polovina, Marija |e verfasserin |4 aut | |
| 700 | 1 | |a Milinković, Ivan |e verfasserin |4 aut | |
| 700 | 1 | |a Nakamura, Kazufumi |e verfasserin |4 aut | |
| 700 | 1 | |a Anker, Stefan D |e verfasserin |4 aut | |
| 700 | 1 | |a Veljić, Ivana |e verfasserin |4 aut | |
| 700 | 1 | |a Ohtani, Tomohito |e verfasserin |4 aut | |
| 700 | 1 | |a Okumura, Takahiro |e verfasserin |4 aut | |
| 700 | 1 | |a Thum, Thomas |e verfasserin |4 aut | |
| 700 | 1 | |a Tschöpe, Carsten |e verfasserin |4 aut | |
| 700 | 1 | |a Rosano, Giuseppe |e verfasserin |4 aut | |
| 700 | 1 | |a Coats, Andrew J S |e verfasserin |4 aut | |
| 700 | 1 | |a Starling, Randall C |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of cardiac failure |d 1995 |g 27(2021), 7 vom: 01. Juli, Seite 727-743 |w (DE-627)NLM087692775 |x 1532-8414 |7 nnns |
| 773 | 1 | 8 | |g volume:27 |g year:2021 |g number:7 |g day:01 |g month:07 |g pages:727-743 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.cardfail.2021.04.010 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 27 |j 2021 |e 7 |b 01 |c 07 |h 727-743 | ||